GlassScriptPhysician profile
Brian S Walther
NPI 1083891568
$2,046.15
in general payments reported to CMS, 2019-2025
18 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.03 · 2020: $17.34 · 2021: $36.65 · 2022: $49.29 · 2023: $89.31 · 2024: $805 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,895.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $613.53 | 2021-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $339.49 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $199.66 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $155.36 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $137.85 | 2024-2025 | |
| Amgen INC. | $126.90 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $94.99 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $78.63 | 2023-2025 | |
| Genzyme Corporation | $60.96 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $50.21 | 2024-2025 | Sotyktu |
| Pfizer INC. | $39.03 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $36.99 | 2025 | Dupixent |
| Journey Medical Corporation | $25.34 | 2025 | |
| Cipher Pharmaceuticals US LLC | $24.05 | 2025 | Spinosad, Natroba |
| Galderma Laboratories, L.P. | $18.39 | 2025 | Nemluvio |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $17.66 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.98 | 2025 | Dupixent |
| Almirall LLC | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Walther listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.